2 Information about upadacitinib

Marketing authorisation indication

2.1 Upadacitinib (Rinvoq, AbbVie) is 'indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for upadacitinib.


2.3 The list price is £805.56 per 28‑tablet pack, with each tablet containing 15 mg of upadacitinib (excluding VAT; BNF online, accessed June 2022). The annual cost of treatment with one 15‑mg tablet per day is £10,501.05 (excluding VAT; BNF online, accessed June 2022)

2.4 The company has a commercial arrangement. This makes upadacitinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)